Lilly says tirzepatide kept obese and overweight people from developing diabetes
After recently reporting soaring sales of its diabetes franchise, Eli Lilly is back with more data on its GLP-1/GIP dual agonist tirzepatide. In a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
